Open access · US-GOV via ClinicalTrials.gov Clinical trial

Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging

Authors not listed

Lewis Lipsitz · 2022

Cellular senescence Senolytics Human Randomized controlled trial

Abstract

The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-17 MST

Cite this

APA

Anonymous. (2022). Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging. <em>Lewis Lipsitz</em>. https://clinicaltrials.gov/study/NCT05422885

Vancouver

Anonymous. Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging. Lewis Lipsitz. 2022.

BibTeX

@misc{anon2022Senoly, title = {Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging}, author = {Anonymous}, journal = {Lewis Lipsitz}, year = {2022}, }